|
Pronunciation |
|
(naf
AZ oh leen & an TAZ oh
leen) |
|
|
U.S. Brand
Names |
|
Albalon-A® Ophthalmic;
Antazoline-V® Ophthalmic; Vasocon-A®[OTC]
Ophthalmic |
|
|
Generic
Available |
|
No |
|
|
Pharmacological Index |
|
Ophthalmic Agent, Vasoconstrictor |
|
|
Use |
|
Topical ocular congestion, irritation and itching |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Angle-closure glaucoma; hypersensitivity to naphazoline or
antazoline |
|
|
Adverse
Reactions |
|
1% to 10%:
Central nervous system: Nervousness, dizziness, headache
Gastrointestinal: Nausea
Local: Transient stinging
Neuromuscular & skeletal: Weakness
Ocular: Mydriasis, increased intraocular pressure, blurring of vision
Respiratory: Nasal mucosa irritation, dryness, rebound congestion
Miscellaneous: Diaphoresis |
|
|
Drug
Interactions |
|
MAO inhibitors |
|
|
Stability |
|
Store in tight, light-resistant containers |
|
|
Usual Dosage |
|
1-2 drops every 3-4 hours |
|
|
Mental Health: Effects
on Mental Status |
|
May cause nervousness or dizziness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
TCAs and MAOIs may potentiate the pressor response of decongestants; monitor
for changes in response |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Do not use discolored solutions |
|
|
Nursing
Implications |
|
Do not use discolored solutions |
|
|
Dosage Forms |
|
Solution: Naphazoline hydrochloride 0.05% and antazoline phosphate 0.5% (15
mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|